Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Pediatric Rheumatology

Living with sJIA: Monitoring and Daily Life

At a Glance

Living with sJIA requires regular blood tests, prompt attention to infection symptoms, and careful review of vaccines, growth, bone health, and emotional well-being. A pediatric rheumatology team helps families manage medicines safely and prepare for adult care.

Living with systemic juvenile idiopathic arthritis (sJIA) is a marathon, not a sprint. While modern biologics have transformed the outlook for many children, the daily reality involves careful monitoring, managing infection risks, and supporting your child’s emotional well-being. Transitioning from the crisis of diagnosis to a “new normal” requires a proactive approach to both physical and mental health.

Routine Laboratory Monitoring

Because biologics like anakinra, canakinumab, and tocilizumab work by quieting the immune system, they require regular blood tests to ensure they are working safely. Your care team will set a specific monitoring schedule to evaluate several key areas:

  • White Blood Cells (Neutrophils): Biologics can sometimes cause neutropenia, a drop in the specific white blood cells that fight infection [1].
  • Liver Enzymes: Both sJIA itself and medications like anakinra can cause the liver to become inflamed. Doctors look for rising transaminases (AST and ALT) to catch this early [2][3].
  • Cholesterol and Lipids: Specifically with tocilizumab, some children develop elevated cholesterol or triglyceride levels, which may need to be monitored over time [1][4].
  • Inflammatory Trends: Regular checks of ferritin, platelets, and fibrinogen are vital. As discussed on the MAS page, a “falling” count in these labs while a child feels sick can be a major warning sign [5][6].

Infection Risks and Vaccines

When your child is on a biologic, their immune system is less able to fight off common bugs. Infections are not only a concern on their own but can also act as a “trigger” for Macrophage Activation Syndrome (MAS) [7][8].

  • Vigilance: Any new fever, persistent cough, or gastrointestinal illness should be reported to your rheumatologist promptly [9][10]. Develop a written sick-day plan with your clinic that clarifies when to call.
  • Non-Live Vaccines: Maintaining non-live vaccinations (like the seasonal flu shot and COVID-19) remains very important and is generally recommended.
  • Live Vaccines: Medical guidance suggests carefully weighing the risks of live-attenuated vaccines (like MMR or chickenpox) while a child is receiving immunosuppression [11]. Decisions should be made strictly with the treating team, as guidance depends on the specific drug and local recommendations. Never hold or restart a biologic on your own.
  • Sick Contacts: If your child is exposed to a live virus like chickenpox or measles, contact your doctor immediately, as they may need specialized treatment to prevent a severe infection [12].

Protecting Growth and Bone Health

The combination of chronic inflammation and glucocorticoid (steroid) use can take a toll on a growing body. About 11% of children with sJIA experience some form of growth retardation, though growth often improves when the inflammation is controlled [13].

  • Growth Tracking: Your doctor will closely monitor your child’s height, weight, and pubertal development at every visit [14][15].
  • Bone Density: Steroids can lead to low bone density and “silent” fractures. Your team may recommend a DXA scan (a specialized bone density X-ray) and ensure your child is getting enough Vitamin D and calcium [16][15].
  • Activity: Weight-bearing activities, like walking or light play, are encouraged to help keep bones strong, provided they are guided by your care team and do not worsen active joint pain [16].

The Emotional and Social Burden

The “invisible” symptoms of sJIA—like fatigue and sleep disturbances—can be just as difficult as the joint pain. Over 50% of children with sJIA report significant sleep impairment, which can lead to irritability and trouble focusing at school [17].

Children may also feel “different” from their peers. Adolescents with sJIA often report hiding their pain or fatigue from friends to fit in [18]. The burden of frequent injections (especially daily anakinra) can lead to “needle phobia” or treatment fatigue [19]. Consider involving a child life specialist or counselor to help your child navigate these feelings. At school, physical or occupational therapy and health accommodations (such as flexibility for fatigue or missed days) can be highly beneficial.

Looking Toward the Future

As your child grows, the goal is to gradually move them toward managing their own care. This process, called transition, usually begins in the early teens [20]. It involves teaching them about their medications, how to recognize flares, and how to communicate with their medical team, ensuring they are ready to move from a pediatric specialist to an adult rheumatologist when the time comes.

Common questions in this guide

What blood tests are usually monitored in a child with sJIA?
The care team may monitor white blood cell counts, including neutrophils that help fight infection, liver enzymes such as AST and ALT, cholesterol and triglycerides, and inflammation-related tests such as ferritin, platelets, and fibrinogen. The schedule depends on your child's medicines and health, so follow the plan from the rheumatology team.
Should I call the doctor if my child with sJIA develops a fever?
Yes. A new fever, persistent cough, or gastrointestinal illness should be reported promptly to the rheumatology team because biologic medicines can reduce the body's ability to fight infection, and infections may trigger macrophage activation syndrome. Ask the clinic for a written sick-day plan, and do not stop, hold, or restart a biologic unless the treating team tells you to.
Which vaccines are safe for children taking sJIA biologics?
Non-live vaccines, including seasonal flu and COVID-19 vaccines, remain important and are generally recommended. Live-attenuated vaccines, such as MMR or chickenpox vaccine, need an individualized decision from the treating team based on the medicine and local guidance; do not change biologic treatment on your own.
How can sJIA and steroids affect my child's growth and bones?
Chronic inflammation and glucocorticoid treatment can slow growth and reduce bone density, sometimes without obvious symptoms. The care team may track height, weight, puberty, and bone density, and may recommend a DXA scan, adequate vitamin D and calcium, and safe weight-bearing activity.
How can we support sleep, fatigue, and emotional health with sJIA?
Fatigue and sleep problems can affect mood, attention, school, and participation with friends, while injections may cause treatment fatigue or needle anxiety. A child life specialist or counselor, along with school accommodations and physical or occupational therapy when appropriate, can help your child cope and stay involved.
When should my child start preparing to manage sJIA independently?
Transition planning often begins in the early teen years. It can include learning medication names and schedules, recognizing flares, speaking with the medical team, and preparing to move from pediatric to adult rheumatology care.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is our specific schedule for blood work to monitor my child's liver enzymes, cholesterol, and white blood cell counts based on their medication?
  2. 2.Since my child is on a biologic, what is the protocol if they are exposed to a live virus like chickenpox or measles?
  3. 3.How are we tracking my child's bone density and growth velocity, especially given their past or current steroid use?
  4. 4.Are there non-live vaccines that my child still needs, and when is the safest time to administer them?
  5. 5.What signs of 'injection fatigue' or psychosocial distress should I look for, and do you have a child life specialist who can help with injection anxiety?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.

    Machado SH, Xavier RM

    Expert opinion on drug safety 2017; (16(4)):493-500 doi:10.1080/14740338.2017.1303479.

    PMID: 28277841
  2. 2

    Drug-induced liver injury secondary to anakinra in a patient with systemic juvenile idiopathic arthritis-Case report and literature overview.

    Mannala S, Kehar M, Samson L, et al.

    Canadian liver journal 2025; (8(4)):591-596 doi:10.3138/canlivj-2025-0039.

    PMID: 41725797
  3. 3

    Anakinra and hepatotoxicity in pediatric rheumatology: a case series.

    Martins FR, Azevedo AC, Ganhão S, et al.

    Pediatric rheumatology online journal 2023; (21(1)):112 doi:10.1186/s12969-023-00891-y.

    PMID: 37803456
  4. 4

    Experience with Cidofovir as an adjunctive therapy in a patient of adenovirus-induced macrophage activation syndrome in systemic arthritis.

    Pal P, Bose N, Poddar A, et al.

    Clinical rheumatology 2020; (39(8)):2449-2452 doi:10.1007/s10067-020-05133-0.

    PMID: 32418043
  5. 5

    Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.

    Chellapandian D, Milojevic D

    Frontiers in pediatrics 2023; (11()):1123104 doi:10.3389/fped.2023.1123104.

    PMID: 36891226
  6. 6

    Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis.

    Schulert GS, Minoia F, Bohnsack J, et al.

    Arthritis care & research 2018; (70(3)):409-419 doi:10.1002/acr.23277.

    PMID: 28499329
  7. 7

    Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.

    Grom AA, Ilowite NT, Pascual V, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2016; (68(1)):218-28 doi:10.1002/art.39407.

    PMID: 26314396
  8. 8

    Macrophage activation syndrome in a patient with systemic onset of the juvenile idiopathic arthritis.

    Jain D, Aggarwal HK, Rao A, et al.

    Reumatologia 2016; (54(1)):42-7 doi:10.5114/reum.2016.58763.

    PMID: 27407277
  9. 9

    PRECORDIAL PAIN, LEUKOCYTOSIS AND BICYTOPENIA IN A TEENAGER WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS UNDER IMMUNOSUPPRESSIVE THERAPY.

    Vieira MS, Andrade FR, Brandão LMKR, et al.

    Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo 2019; (37(2)):252-256 doi:10.1590/1984-0462/;2019;37;2;00004.

    PMID: 30810692
  10. 10

    Severe sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: a case report.

    Xu M, Liu C, Guo L, Yang S

    BMC pediatrics 2020; (20(1)):126 doi:10.1186/s12887-020-02032-w.

    PMID: 32188441
  11. 11

    The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey.

    Jeyaratnam J, Ter Haar NM, Lachmann HJ, et al.

    Pediatric rheumatology online journal 2018; (16(1)):19 doi:10.1186/s12969-018-0235-z.

    PMID: 29562920
  12. 12

    Primary varicella infection in children with systemic juvenile idiopathic arthritis under tocilizumab therapy.

    Nozawa T, Nishimura K, Ohara A, et al.

    Modern rheumatology 2019; (29(3)):558-562 doi:10.1080/14397595.2016.1254314.

    PMID: 27846755
  13. 13

    Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience.

    Barut K, Adrovic A, Sahin S, et al.

    International journal of rheumatic diseases 2019; (22(9)):1661-1669 doi:10.1111/1756-185X.13649.

    PMID: 31273940
  14. 14

    Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013.

    Klotsche J, Raab A, Niewerth M, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2016; (68(12)):3023-3034 doi:10.1002/art.39796.

    PMID: 27332999
  15. 15

    Bone Health in Children with Rheumatic Disorders: Focus on Molecular Mechanisms, Diagnosis, and Management.

    Di Marcello F, Di Donato G, d'Angelo DM, et al.

    International journal of molecular sciences 2022; (23(10)) doi:10.3390/ijms23105725.

    PMID: 35628529
  16. 16

    Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.

    Zhang Y, Milojevic D

    Paediatric drugs 2017; (19(3)):193-211 doi:10.1007/s40272-017-0219-3.

    PMID: 28290112
  17. 17

    Utility of patient-reported outcomes for pulmonary symptoms and sleep disturbance and impairment in children with systemic juvenile idiopathic arthritis.

    Nguyen K, Yasin S, Fall N, et al.

    Pediatric rheumatology online journal 2025; (23(1)):74 doi:10.1186/s12969-025-01126-y.

    PMID: 40665383
  18. 18

    Impact of systemic juvenile idiopathic arthritis/Still's disease on adolescents as evidenced through social media posts.

    Modica RF, Lomax KG, Batzel P, Cassanas A

    Open access rheumatology : research and reviews 2018; (10()):73-81 doi:10.2147/OARRR.S165010.

    PMID: 29942167
  19. 19

    Tofacitinib as an adjuvant treatment for pediatric Still's disease.

    Hou L, Zhou P, Zhao C, et al.

    Frontiers in pediatrics 2025; (13()):1650675 doi:10.3389/fped.2025.1650675.

    PMID: 40909428
  20. 20

    Extraarticular manifestations of juvenile idiopathic arthritis and their impact on health-related quality of life.

    Tharwat S, Nassar MK, Salem KM, Nassar MK

    Clinical rheumatology 2024; (43(7)):2295-2305 doi:10.1007/s10067-024-07008-0.

    PMID: 38797812

This page is for informational purposes only and does not constitute medical advice. Your child's pediatric rheumatology team should guide medication changes, vaccine decisions, infection care, activity, and monitoring.

Get notified when new evidence is published on Systemic-onset juvenile idiopathic arthritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.